Oncology
Malignant Tumors
2
Pipeline Programs↗
29
Active Trials↗
19
Companies Involved↗
Malignant Tumors is an early-stage landscape with 2 programs across 19 companies. The most active players are Bayer, LaNova Medicines Limited, BeiGene.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 67% of 3 pipeline programs.
Analysis
Trial Status
65
clinical trials
Completed18 · 28%
Unknown status17 · 26%
Recruiting17 · 26%
Not yet recruiting9 · 14%
Active, not recruiting2 · 3%
Enrolling by invitation1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
65 trials
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
Recruiting·—·Phase 2/3·NCT05749302·500 enrolled
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Recruiting·—·Phase 1·NCT05631886·10 enrolled
Genetically Modified T Cells Treating Malignant Tumors
Recruiting·—·Phase 1·NCT06515626·100 enrolled
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
Recruiting·—·N/A·NCT06684028·30 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)